Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity | Zendy

Marylyn D. Ritchie | Zendy; David W. Haas | Zendy; Alison A. MotsingerReif | Zendy; John P. Donahue | Zendy; Hasan Erdem | Zendy; Stephen Raffanti | Zendy; Peter F. Rebeiro | Zendy; Alfred L. George | Zendy; Richard B. Kim | Zendy; J.L. Haines | Zendy; T. R. Sterling | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity

Author(s) -

Marylyn D. Ritchie,

David W. Haas,

Alison A. MotsingerReif,

John P. Donahue,

Hasan Erdem,

Stephen Raffanti,

Peter F. Rebeiro,

Alfred L. George,

Richard B. Kim,

J.L. Haines,

T. R. Sterling

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/507101

Subject(s) - efavirenz , nevirapine , medicine , cyp2b6 , cyp3a4 , reverse transcriptase inhibitor , pharmacology , reverse transcriptase , odds ratio , virology , liver enzyme , gene , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , polymerase chain reaction , biology , cytochrome p450 , genetics , metabolism

This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P<.001).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research